Display options
Share it on

Clin Transl Gastroenterol. 2013 May 16;4:e34. doi: 10.1038/ctg.2013.5.

MicroRNA Expression Profiling in the Histological Subtypes of Barrett's Metaplasia.

Clinical and translational gastroenterology

Matteo Fassan, Stefano Volinia, Jeff Palatini, Marco Pizzi, Cecilia Fernandez-Cymering, Mariangela Balistreri, Stefano Realdon, Giorgio Battaglia, Rhonda Souza, Robert D Odze, Giovanni Zaninotto, Carlo M Croce, Massimo Rugge Md Facg

Affiliations

  1. 1] Department of Medicine (DIMED), Surgical Pathology and Cytopathology Unit, University of Padua, Padua, Italy [2] Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), General Oncology Unit, University of Padua, Padua, Italy.

PMID: 23677165 PMCID: PMC3671360 DOI: 10.1038/ctg.2013.5

Abstract

OBJECTIVES: The histological definition of Barrett's esophagus (BE) is debated, particularly regarding the phenotype of its metaplastic columnar epithelium. Histologically proven intestinal metaplasia (IM) was the sine qua non condition for a diagnosis of BE but, more recently, non-intestinalized (i.e., cardiac gastric-type; GM) columnar metaplasia has been re-included in the spectrum of Barrett's histology. MicroRNAs modulate cell commitment, and are also reportedly dysregulated in Barrett's carcinogenesis. This study investigates miRNA expression in the histological spectrum of esophageal columnar metaplastic changes, specifically addressing the biological profile of GM vs. IM.

METHODS: A study was performed to discover microRNA microarray in 30 matching mucosa samples obtained from 10 consecutive BE patients; for each patient, biopsy tissue samples were obtained from squamous, GM and intestinalized epithelium. Microarray findings were further validated by qRT-PCR analysis in another bioptic series of 75 mucosa samples.

RESULTS: MicroRNA profiling consistently disclosed metaplasia-specific microRNA signatures. Six microRNAs were significantly dysregulated across the histological phenotypes considered; five of them (two overexpressed (hsa-miR-192; -miR-215) and three under-expressed (hsa-miR-18a*; -miR-203, and -miR-205)) were progressively dysregulated in the phenotypic sequence from squamous to gastric-type, to intestinal-type mucosa samples.

CONCLUSIONS: A consistent microRNA expression signature underlies both gastric- and intestinal-type esophageal metaplasia. The pattern of microRNA dysregulation suggests that GM may further progress to IM. The clinico-pathological implications of these molecular profiles prompt further study on the "personalized" cancer risk associated with each of these metaplastic transformations.

References

  1. Gastroenterology. 2009 May;136(5):1689-700 - PubMed
  2. Int J Cancer. 2011 Oct 1;129(7):1661-70 - PubMed
  3. Cancer Cell. 2004 Jul;6(1):11-6 - PubMed
  4. Clin Cancer Res. 2009 Sep 15;15(18):5744-52 - PubMed
  5. Dig Liver Dis. 2007 Jan;39(1):18-25 - PubMed
  6. Hum Pathol. 2009 Aug;40(8):1206-7; author reply 1207-8 - PubMed
  7. World J Gastroenterol. 2011 Dec 28;17(48):5231-9 - PubMed
  8. Dig Liver Dis. 2011 Mar;43 Suppl 4:S319-30 - PubMed
  9. Lancet. 2000 Dec 16;356(9247):2079-85 - PubMed
  10. J Pathol. 2009 Oct;219(2):214-21 - PubMed
  11. Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 - PubMed
  12. Am J Gastroenterol. 2000 May;95(5):1152-7 - PubMed
  13. Am J Surg Pathol. 2009 Jun;33(6):818-25 - PubMed
  14. Dig Liver Dis. 2011 Mar;43(3):246 - PubMed
  15. BMC Cancer. 2011 Feb 07;11:57 - PubMed
  16. Mol Biotechnol. 2012 Feb;50(2):159-69 - PubMed
  17. Curr Opin Pharmacol. 2009 Dec;9(6):727-32 - PubMed
  18. J Natl Cancer Inst. 2012 Nov 21;104(22):1771-2 - PubMed
  19. Nat Genet. 2006 Mar;38(3):356-62 - PubMed
  20. Gut. 2013 May;62(5):664-75 - PubMed
  21. J Natl Cancer Inst. 2011 Jul 6;103(13):1049-57 - PubMed
  22. Gastroenterology. 2011 Mar;140(3):1084-91 - PubMed
  23. Nat Rev Gastroenterol Hepatol. 2009 Aug;6(8):478-90 - PubMed
  24. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 - PubMed
  25. Gut. 2006 Dec;55(12):1810-20 - PubMed
  26. Br J Surg. 2010 Jun;97(6):853-61 - PubMed
  27. Cancer Res. 2008 Dec 15;68(24):10094-104 - PubMed
  28. Gastroenterology. 2011 Mar;140(3):e18-52; quiz e13 - PubMed
  29. Am J Gastroenterol. 2009 Apr;104(4):816-24 - PubMed
  30. Gastroenterologia. 1956;86(3):183-6 - PubMed
  31. RNA. 2008 Jul;14(7):1433-42 - PubMed
  32. Am J Gastroenterol. 2009 Oct;104(10):2588-94 - PubMed
  33. Cell Death Differ. 2008 Jul;15(7):1187-95 - PubMed
  34. J Clin Pathol. 2010 Aug;63(8):692-6 - PubMed
  35. Hum Pathol. 2009 Jan;40(1):65-74 - PubMed
  36. J Thorac Cardiovasc Surg. 2008 Feb;135(2):255-60; discussion 260 - PubMed
  37. Am J Surg Pathol. 2009 Jul;33(7):1006-15 - PubMed
  38. Nat Rev Genet. 2009 Oct;10(10):704-14 - PubMed
  39. N Engl J Med. 2011 Oct 13;365(15):1375-83 - PubMed
  40. Cancer Res. 2008 Dec 15;68(24):10105-12 - PubMed
  41. Am J Gastroenterol. 2011 Jun;106(6):1055-63 - PubMed
  42. Biochem Biophys Res Commun. 2007 Jun 22;358(1):12-7 - PubMed

Publication Types